This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Bio-Rad
other brands :
Biogenesis, Serotec, AbD Serotec, Oxford Biotechnology
product type :
antibody
product name :
NEMO-LIKE KINASE antibody
catalog :
VMA00357KT
quantity :
2 Westerns
price :
108 USD
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
reactivity :
human
application :
western blot
product information
EntityType :
PrecisionAbâ„¢ Monoclonal
EntityCategory :
Antibodies
ProductCode :
VMA00357KT
Description :
NEMO-LIKE KINASE ANTIBODY WITH CONTROL LYSATE
Specificity :
NEMO-LIKE KINASE
TargetSpecies :
Human
Host :
Mouse
Format :
Purified
Isotypes :
IgG2a
Applications :
WB
ApplicationTypes :
Western Blotting
Quantity :
2 Westerns
QuantityValue :
2
QuantityType :
Westerns
GOAccessions :
GO:0000287, GO:0004707, GO:0016055, GO:0005524, GO:0005634, GO:0005737, GO:0006350, GO:0007179, GO:0008134, GO:0018107, GO:0030178, GO:0031625, GO:0033136, GO:0042169, GO:0045449
GOTerms :
ATP:protein phosphotransferase (MAPKK-activated) activity, cell nucleus, cellular transcription, down regulation of frizzled signaling pathway, down regulation of Wnt receptor signaling pathway, downregulation of frizzled signaling pathway, down-regulation of frizzled signaling pathway, downregulation of Wnt receptor signaling pathway, down-regulation of Wnt receptor signaling pathway, Dp38, ERK, ERK1, ERK2, extracellular signal-regulated kinase activity, frizzled signaling pathway, frizzled signalling pathway, GO:0007222, GO:0008338, GO:0008339, GO:0016908, GO:0045810, GO:0061018, GO:0061019, inhibition of frizzled signaling pathway, inhibition of Wnt receptor signaling pathway, LeMPK3, magnesium binding, MAP kinase 1 activity, MAP kinase 2 activity, MAP-2 kinase activity, MAPK, MBP kinase I activity, MBP kinase II activity, mitogen activated kinase activity, mitogen-activated protein kinase activity, MP kinase activity, Mpk2, myelin basic protein kinase activity, negative regulation of frizzled signaling pathway, negative regulation of frizzled signalling pathway, negative regulation of Wnt receptor signalling pathway, p38, p38-2, p38delta, p42 mitogen-activated protein kinase activity, p42mapk, p44mpk, PMK-1, PMK-2, PMK-3, pp42, pp44mapk, regulation of cellular transcription, SAPK2, STK26, TF binding, TGFbeta receptor signaling pathway, TGF-beta receptor signaling pathway, TGFbeta receptor signalling pathway, TGF-beta receptor signalling pathway, transforming growth factor beta receptor signalling pathway, ubiquitin ligase binding, Wg signaling pathway, Wg signalling pathway, Wingless signaling pathway, Wingless signalling pathway, Wnt receptor signalling pathway
UniprotAccessions :
Q9UBE8
Gene :
NLK
GeneID URL :
www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=51701
EntityFormats :
Purified
UNSPSC :
12352203
ProductForm :
Purified IgG - liquid
PriceDKK :
804
PrimarySecondary :
Primary
PriceGBP :
83
PriceEUR :
108
PriceUSD :
108 USD
PriceCHF :
126
PriceSEK :
1077
PriceNOK :
1070
company information
Bio-Rad
Endeavour House, Langford Business Park
Langford Lane, Kidlington
OXON, OX5 1GE
antibody_sales_uk@bio-rad.com
https://www.bio-rad-antibodies.com
1 800 265 7376 (North America)
44 (0)1865 852 700 (Rest of World)
headquarters: UK
Bio-Rad is one of the world's leading antibody manufacturers, offering over 12,000 antibodies and related reagents for a focused range of research areas such as immunology, cancer, veterinary research and cell biology through its antibody experts formerly known as AbD Serotec.
The range includes apoptosis kits, autophagy reagents, CD markers, epitope tag antibodies, immunology antibodies, neuroscience antibodies, and veterinary reagents.
Bio-Rad has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as ISO 9001 certified facilities in Germany and the United States.
Our expertise extends to traditional and recombinant antibody generation and production services. Our custom generation service delivers antibodies in as little as 8 weeks with greater than 90% success. The in vitro technology enables selection of antibodies to challenging targets, long term consistent supply, and provision of the antibody sequence.
At Bio-Rad we are committed to your success when using our antibodies and we focus on providing the technology, products and all the supporting information you need to excel in your research.